DiagnoCure previews Previstage GCC to key audiences



    Promising New Colorectal Cancer Diagnostic Staging Test Exhibited at ASCO
    GI Conference

    Ticker Symbol: CUR

    WEST CHESTER, PA, Jan. 24 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a
life sciences company commercializing high-value cancer diagnostic tests, and
its subsidiary, DiagnoCure Oncology Laboratories based in West Chester, PA,
near Philadelphia will exhibit at the American Society of Clinical Oncology -
The Gastrointestinal Cancers Symposium (ASCO GI) beginning tomorrow
January 25th in Orlando, Florida. The Company will familiarize attendees with
the science behind its Previstage(TM) GCC Colorectal Cancer Staging Test. The
ASCO GI symposium is a major meeting of surgeons, oncologists, radiologists
and other clinical specialists who focus on treating patients with colorectal
and other cancers of the gastrointestinal tract.
    Previstage GCC identifies the expression of the guanylyl cyclase C (GCC)
gene, a biomarker that is normally found exclusively in the intestine.
Extensive research conducted by Dr. Scott Waldman at Thomas Jefferson
University has determined that when the expression of GCC mRNA is detected
outside of the intestine (such as in the lymph nodes), it is a highly
sensitive, early indication that colorectal cancer has spread. The Previstage
GCC test employs RT-PCR technology, which has been shown to be up to
100,000-times more sensitive than traditional histopathology in detecting
occult metastases. The technology can detect one cancer cell in up to 10
million cells, versus one in 200 normal cells with traditional methods. The
Previstage GCC test should provide clinicians a significantly more sensitive
tool than traditional histopathology review alone for staging a patient with
colorectal cancer and therefore may help the physician determine the most
appropriate course of treatment.
    "We are very excited to begin educating the important audience at the
ASCO GI meeting about the relevant science behind Previstage GCC," stated John
Schafer, President and CEO of DiagnoCure. "We look forward to bringing this
test to market to potentially help both clinicians and patients make even more
confident decisions with regards to colorectal cancer treatment and whether a
patient requires chemotherapy after surgery."
    DiagnoCure Oncology Laboratories will be the only facility to offer the
Previstage GCC Colorectal Cancer Staging Test. The Company's target is for its
Pennsylvania-based laboratory to be CLIA certified and begin exclusively
offering this high-value diagnostic test for the staging of colorectal cancer
in the second half of 2008.

    About Previstage(TM) GCC

    Staging a patient with colorectal cancer is crucial because it determines
the patient's course of treatment. Current standard of care requires that
pathologists examine microscopically a thin slice of tissue from each of 12 or
more lymph nodes harvested during the patient's surgery to see if cancer has
spread beyond the intestine. Currently as many as 30% of patients with no
pathologically-positive lymph nodes (stage I and II cancers) later return with
recurrent disease, presumably through occult metastases that have escaped
detection. Most of these patients do not receive additional therapies such as
chemotherapy. Previstage GCC aims to provide clinicians a significantly more
sensitive tool for staging a patient with colorectal cancer.
    Strong early data supported the potential importance of the GCC test in
improving the staging of colorectal patients. This resulted in the National
Cancer Institute sponsoring a prospective clinical trial of GCC testing in
approximately 1,000 colorectal cancer patients conducted over five years. This
study has been completed and the Company's collaborators at Thomas Jefferson
University will be presenting the results of the study at major medical
conferences later this year.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. DiagnoCure is currently preparing to launch the Previstage(TM) GCC
Colorectal Cancer Staging Test, the first GCC-based molecular test for the
management of colorectal cancer. In 2003, the Company entered into a strategic
alliance with Gen-Probe (NASDAQ:   GPRO) for the development and
commercialization of a second-generation test for PCA3, DiagnoCure's
proprietary molecular marker highly specific to prostate cancer. The test is
now available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA(TM)
PCA3 in vitro assay. In addition to its own research, the Company intends to
acquire or in-license additional promising cancer biomarkers from both
academic and commercial institutions. For more information visit
www.diagnocure.com.

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.
    %SEDAR: 00003671EF




For further information:

For further information: DiagnoCure Inc.: John C. Schafer, President and
Chief Executive Officer; Paule De Blois, Vice President, Corporate Affairs,
(418) 527-6100, communications@diagnocure.com; U.S.: Karen Sparks, Mentus Life
Science, (858) 455-5500 X275, Karen@mentus.com; Canada: Jean-Pierre Trudel,
Jean-Pierre Trudel & Associates, (514) 347-6111, jp.trudel@videotron.ca

Organization Profile

DiagnoCure Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890